Sponsored Content

As the monoclonal-antibody (mAb) market continues to grow, it is becoming increasingly important for pharmaceutical and biotech companies to accelerate process development and establish a scalable manufacturing process capable of achieving high titers and consistent product quality. Central to this is a cell culture media and feed system that can provide the required nutrients for optimal cell growth, viability, and function, as well as facilitate a seamless transition from development to clinical and commercial manufacturing. However, choosing an appropriate system can be a complex and time-consuming process, often requiring the evaluation of multiple medium and feed options. Platform systems, consisting of a medium and complementary feed developed for a specific cell line and application, have emerged as a valuable option for developers to help simplify selection and increase scale-up efficiency. To meet the need for high-performance platform mAb manufacturing solutions, Thermo Fisher Scientific has dev...

Sponsored Content

This webcast features: Hakyung Kim, Senior Scientist, Upstream Process Development & Dongyoung Park, Senior Scientist, Upstream Process Development, Samsung Biologics. Recent innovations in intensified fed-batch (IFB) processing have dramatically improved cell culture yields and scalability, offering a powerful solution for optimizing biopharmaceutical production. By incorporating the IFB approach, Samsung Biologics has developed a platform that optimizes crucial process parameters to maximize the productivity of cultured cell lines. Join Samsung Biologics for this webinar as they explore the latest advancements in IFB processing and discuss how our novel platform, S-Tensify™, ensures consistent quality and productivity in an increasingly complex production landscape. Key Takeaways: Register or Login and hit Watch on Demand to view the recorded webcast now.